GI Innovation지아이이노베이션
358570 · KOSDAQ · ₩358570 · 지아이이노베이션
₩7,140▲ ₩110 (1.56%)End-of-day · Oct 28, 2026 · End-of-day prices.
Filings
- Major management matter relevant to investors투자판단관련주요경영사항 (GI301의 일본 내 마일스톤 기술료 수령예정)Oct 23, 2026Open on DART
Predicted impact: Medium
Expected milestone fee for GI301 in Japan; amount unknown, but last year's revenue was only 5.5 billion won.
- 5%+ holding report주식등의대량보유상황보고서(일반)Oct 7, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(임상시험계획변경승인) (GI102 제1/2상 임상시험계획 변경승인 )Oct 1, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Sep 4, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인신청) (GI102 제1/2상 임상시험계획 호주 인체연구윤리위원회 (HREC) 변경승인 신청)Aug 21, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(약식)Aug 20, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 10, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 10, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 10, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 10, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 10, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 10, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Aug 6, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 23, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 23, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 13, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인) (GI108 제1/2a상 임상시험계획 한국식품의약품안전처 변경승인)Jul 10, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Jul 6, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 6, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (전이성 거세저항성 전립선암 환자를 대상으로 GI102와 pasritamig 병용 요법의 항암 활성, 안전성 및 내약성을 평가하기 위한 제1b/2상 임상시험계획 승인)Jun 30, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인신청) (진행성 또는 전이성 고형암 시험대상자를 대상으로 GI108 단일 요법의 안전성, 내약성, 약동학 및 치료효과를 평가하기 위한 제1/2a상 임상시험 계획 변경승인신청)Jun 8, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Jun 8, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jun 5, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jun 5, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jun 5, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jun 5, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jun 5, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jun 5, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (전이성 거세저항성 전립선암 환자를 대상으로 GI102와 pasritamig 병용 요법의 항암 활성, 안전성 및 내약성을 평가하기 위한 제1b/2상 임상시험계획 승인)May 29, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (전이성 거세저항성 전립선암 환자를 대상으로 GI102와 pasritamig 병용 요법의 항암 활성, 안전성 및 내약성을 평가하기 위한 제 1b/2상 임상시험계획 승인 신청)May 28, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
- Share cancellation decision주식소각결정May 13, 2026Open on DART
- [Amended] Notice of Stock Purchase Option Grant[기재정정]주식매수선택권부여에관한신고May 13, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(임상시험계획변경승인) ( GI102 제1/2상 임상시험계획 변경승인 )Apr 23, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청등결정) (전이성 거세저항성 전립선암 환자를 대상으로 GI102와 pasritamig 병용 요법의 항암 활성, 안전성 및 내약성을 평가하기 위한 제 1b/2상 임상시험계획 승인)Apr 20, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Apr 20, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Apr 3, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 27, 2026Open on DART
- Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Mar 27, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 27, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청) (전이성 거세저항성 전립선암 환자를 대상으로 GI102와 pasritamig 병용 요법의 항암 활성, 안전성 및 내약성을 평가하기 위한 제 1b/2상 임상시험계획 승인 신청)Mar 19, 2026Open on DART
- Audit report submitted감사보고서제출Mar 18, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Mar 18, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 18, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(임상시험계획변경승인) (GI102 제1/2상 임상시험계획 변경승인)Mar 13, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(임상시험계획변경승인) (GI102 제1/2상 임상시험계획 변경승인)Mar 12, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Mar 10, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Mar 9, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Mar 9, 2026Open on DART
Titles in Korean until English translations are added.
Also known as: GI Innovation / 지아이이노베이션 / 358570 / KRX:358570
Source: KRX statistical information